Stockscreener 앱 받기
13.97
1.69%
-0.24
시간 외 거래:
13.97
전일 마감가:
$14.21
열려 있는:
$14.23
하루 거래량:
964.55K
Relative Volume:
1.39
시가총액:
$884.60M
수익:
$202.09M
순이익/손실:
$-61.69M
주가수익비율:
-12.94
EPS:
-1.08
순현금흐름:
$-35.64M
1주 성능:
-1.83%
1개월 성능:
+26.54%
6개월 성능:
+12.48%
1년 성능:
+10.09%
1일 변동 폭
$13.88
$14.58
1주일 범위
$13.83
$14.92
52주 변동 폭
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
EOLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
13.97 | 884.60M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Global Jeuveau Market Insights 2025: Key Trends, Market Size, and Growth Forecast - EIN News
Barclays Raises Evolus (NASDAQ:EOLS) Price Target to $22.00 - MarketBeat
Stifel maintains Buy on Evolus, price target steady at $25 - MSN
Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal
FY2029 Earnings Estimate for Evolus Issued By HC Wainwright - MarketBeat
HC Wainwright Weighs in on Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? - MSN
Evolus, Inc. (NASDAQ:EOLS) Soars 30% But It's A Story Of Risk Vs Reward - Simply Wall St
HC Wainwright Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS) - MarketBeat
4 Analysts Have This To Say About Evolus - Benzinga
Evolus projects robust 2025 growth with upcoming product launches By Investing.com - Investing.com Australia
Stifel maintains Buy on Evolus, price target steady at $25 By Investing.com - Investing.com South Africa
Evolus projects robust 2025 growth with upcoming product launches - MSN
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance - BioSpace
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why - Yahoo! Voices
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates - Benzinga
Evolus Shares Surge 34% on Record Q4 Revenue and FDA Approval Ex - GuruFocus.com
Evolus (NASDAQ:EOLS) Receives Buy Rating from Needham & Company LLC - MarketBeat
Evolus (NASDAQ:EOLS) Shares Gap UpHere's What Happened - MarketBeat
Evolus shares surge on strong Q4 results and upbeat 2025 outlook - MSN
Evolus announces Q4 preliminary unaudited net revenue of $79M - MSN
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
Evolus Shares Rise on Jump in Revenue -January 21, 2025 at 09:28 am EST - Marketscreener.com
Evolus Shares Rise on Jump in Revenue - MarketWatch
Evolus shares surge on strong Q4 results and upbeat 2025 outlook By Investing.com - Investing.com South Africa
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Evolus Awards 15,332 RSUs to New Employees Under 2023 Inducement Plan - StockTitan
Trend Tracker for (EOLS) - Stock Traders Daily
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25 (NASDAQ:EOLS) - Seeking Alpha
Evolus (NASDAQ:EOLS) Hits New 1-Year LowHere's Why - MarketBeat
Barclays PLC Buys 68,213 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Possible Bearish Signals With Evolus Insiders Disposing Stock - Simply Wall St
Evolus stock touches 52-week low at $10.23 amid market shifts - Investing.com Nigeria
Evolus (NASDAQ:EOLS) Sets New 52-Week LowHere's What Happened - MarketBeat
EVOLUS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased E - PR Newswire
(EOLS) Technical Data - Stock Traders Daily
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.19%
0.06%
자본화:
|
볼륨(24시간):